Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth [Yahoo! Finance]
Context Therapeutics Inc. (CNTX)
Company Research
Source: Yahoo! Finance
For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. Given this risk, we thought we'd take a look at whether Context Therapeutics NASDAQ:CNTX ) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn. A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at December 2024, Context Therapeutics had cash of US$94m and no debt. Looking at the last year, the company burnt through US$29m. That means it had a cash runway of about 3.2 years as of December 2024. A runway of this length affords the company the time and space it n
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CNTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CNTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual MeetingGlobeNewswire
- Context Therapeutics GAAP EPS of -$0.10 misses by $0.01 [Seeking Alpha]Seeking Alpha
- Context Therapeutics (NASDAQ:CNTX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
CNTX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form 8-K
- CNTX's page on the SEC website